Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia

Haematologica

Volumn 92, Issue 11, 2007, Pages 1574-1575

  De Vries, Andrica C H ^a   Stam, Ronald W ^a   Kratz, Christian P ^b   Zenker, Martin ^c   Niemeyer, Charlotte M ^a,b   Van Den Heuvel Eibrink, Marry M ^a,d  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

BRAF; Juvenile myelomonocytic leukemia

Indexed keywords

ARTICLE; BRAF ONCOGENE; DISEASE ASSOCIATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; NEUROFIBROMATOSIS; ONCOGENE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

CHILD; DNA MUTATIONAL ANALYSIS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 36348986709     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11493     Document Type: Article

References (9)

1. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77:925-9.
2. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994;84:3435-9.
3. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005;106:2183-5.
4. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998;92:267-72.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
6. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Santa Cruz M, et al. Germline mutations in genes within the MAPK pathway cause cardio-faciocutaneous syndrome. Science 2006;311:1287-90.
7. Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. J Mol Med 2007;85:223-31.
8. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-82.
9. Archambeault S, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, et al. Development of an allele-specific minimal residual disease assay for patients with Juvenile Myelomonocytic Leukemia-moving beyond clinical assessment. Blood 2006;108:[ASH Annual Meeting Abstracts].